Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $21.00

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has earned an average recommendation of “Buy” from the eight research firms that are presently covering the company, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $21.00.

A number of brokerages have recently commented on ZVRA. Guggenheim initiated coverage on Zevra Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $20.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a report on Wednesday, November 20th. JMP Securities began coverage on shares of Zevra Therapeutics in a report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price objective on the stock. Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. Finally, Roth Mkm lifted their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th.

Institutional Trading of Zevra Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC raised its holdings in shares of Zevra Therapeutics by 282,687.5% in the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after buying an additional 2,312,384 shares in the last quarter. Stonepine Capital Management LLC bought a new stake in Zevra Therapeutics in the third quarter valued at $4,858,000. Vestal Point Capital LP acquired a new position in Zevra Therapeutics during the third quarter worth $3,644,000. Propel Bio Management LLC bought a new position in shares of Zevra Therapeutics during the third quarter valued at $1,248,000. Finally, Geode Capital Management LLC boosted its stake in shares of Zevra Therapeutics by 14.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock valued at $7,246,000 after purchasing an additional 129,600 shares in the last quarter. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Stock Up 5.0 %

Zevra Therapeutics stock opened at $8.76 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. Zevra Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $9.76. The firm has a fifty day moving average price of $8.75 and a two-hundred day moving average price of $7.45. The firm has a market cap of $467.57 million, a price-to-earnings ratio of -4.45 and a beta of 1.97.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The business had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. During the same period in the prior year, the firm posted ($0.40) EPS. As a group, analysts forecast that Zevra Therapeutics will post -1.96 earnings per share for the current year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.